cyc 202 has been researched along with Metabolic Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortez, BN; Desevin, K; Emili, A; Farmer, SR; Hekman, R; Lin, JZ; Rabhi, N | 1 |
| Armour, S; Chiao, J; Delbaldo, C; Diéras, V; Faivre, S; Frame, S; Gianella-Borradori, A; Girre, V; Green, SR; Laurence, V; Le Tourneau, C; Raymond, E; Vera, K | 1 |
1 trial(s) available for cyc 202 and Metabolic Diseases
| Article | Year |
|---|---|
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Male; Maximum Tolerated Dose; Metabolic Diseases; Middle Aged; Nausea; Neoplasms; Purines; Roscovitine; Vomiting | 2010 |
1 other study(ies) available for cyc 202 and Metabolic Diseases
| Article | Year |
|---|---|
The cyclin dependent kinase inhibitor Roscovitine prevents diet-induced metabolic disruption in obese mice.
Topics: Animals; Cyclin-Dependent Kinases; Diet, High-Fat; Lipolysis; Male; Metabolic Diseases; Mice; Obesity; Roscovitine; Second Messenger Systems; Thermogenesis | 2021 |